MicroRNA‐150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson's disease

Li, Haiting; Yu, Liguo; Min, Li; Chen, Xiaohui; Tian, Qun; Jiang, Yanyan; Li, Nan

doi:10.1002/mgg3.1189

Cited by 42 publications

(47 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4B), which suggested that these miRNAs could possibly participate in both iRBD and PD. Consistent with this hypothesis, miR-150-5p expression was previously reported to be dysregulated during PD progression 50 . Extensive research conducted on let-7 revealed that let-7 could be involved in regulating neuronal degeneration in PD 51 and recognized by TLR7 to promote in ammation and neuronal death 52 .…”

Section: Consistently Altered Ev Mirnas In a Healthy-irbd-pd Hierarchysupporting

confidence: 66%

MicroRNA Candidate Biomarkers for Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Parkinson’s disease (PD), a severe neurodegenerative disorder, and idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD), a parasomnia recognized as the prodromal stage of synucleinopathies (including PD), both lack reliable, non-invasive biomarker tests for early intervention and management. Objectives: To investigate whether plasma extracellular vesicle (EV)-associated sncRNAs could discriminate PD and/or iRBD patients from healthy individuals.Methods: We optimized a cDNA library construction method, EVsmall-seq, for high throughput sequencing of sncRNAs associated with plasma EVs. We profiled EV-sncRNAs from the plasma of 60 normal controls, 56 iRBD patients, and 53 PD patients, and constructed a support vector machine (SVM) classifier to identify the informative miRNA features to distinguish PD and/or iRBD patients from healthy individuals. Results: First, a sixteen-miRNA signature was found to distinguish PD patients from healthy individuals with 88% sensitivity, 90.43% specificity, and 89.13% accuracy. Second, a three-miRNA signature was found to distinguish iRBD patients from healthy individuals with 96% sensitivity, 86.36% specificity, and 91.49% accuracy. Third, tweenty 20 miRNAs were found consistently increased or decreased in expression from healthy subjects to iRBD to PD patients, which might be linked to PD development through iRBD.Conclusions: Current study provides a valuable and highly informative dataset of EV-associated sncRNAs from plasma of iRBD and PD patients. We identified miRNA signature features that could serve as minimally-invasive, blood-based surveillance biomarkers for distinguishing iRBD or PD from healthy individuals with high sensitivity, specificity, and accuracy.

show abstract

Section: Consistently Altered Ev Mirnas In a Healthy-irbd-pd Hierarchysupporting

confidence: 66%

MicroRNA Candidate Biomarkers for Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The crucial role of miRNAs in the diagnosis, pathogenesis, and treatment of PD has been reported by many studies [21]. In a previous study, miR-150-5p was observed to be expressed at low level in the serum of PD patients [22]. In addition, high levels of miR-150-5p have also been detected in patients with Alzheimer's disease [23].…”

Section: Discussionmentioning

confidence: 92%

LncRNA RMST Regulates Neuronal Apoptosis and Inflammatory Response via Sponging miR-150-5p in Parkinson’s Disease

Chuanlei

Zhang

Wei

et al. 2021

Neuroimmunomodulation

View full text Add to dashboard Cite

Introduction: LncRNA rhabdomyosarcoma 2-associated transcript (RMST) serves as a key regulator in neural stem cell fate and is involved in the progression of different neurological diseases. In this research, the serum level and clinical value of RMST in Parkinson’s disease (PD) patients were detected, and the underlying mechanism was explored. Methods: Ninety-nine PD patients and 93 healthy individuals were collected for clinical experiments. SH-SY5Y cells were treated with the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) to establish PD cell models. qRT-PCR was used for the detection of mRNA levels. CCK-8 and flow cytometry were used to detect neuronal viability and apoptosis. The target relationship of RMST with miR-15a-5p was confirmed applying luciferase reporter assay. Results: RMST was present at high levels in both serum of PD patients and PD cell models. Serum RMST had a certain clinical value for the diagnosis of PD with the AUC of 0.892 at a cutoff value of 1.225. Serum RMST was positively associated with the levels of TNF-α (r = 0.421, p < 0.001) and IL-1β (r = 0.567, p < 0.001) in PD patients. Knockdown of RMST alleviated the apoptosis and inflammatory response of SH-SY5Y cells induced by MPP+. miR-150-5p was the target gene of RMST and less expressed in the clinical serum samples and PD cell models. Conclusion: Serum RMST serves as a promising biomarker for the diagnosis of PD. RMST downregulation may regulate the occurrence and development of PD through inhibiting neuron cell apoptosis and the release of inflammatory cytokines via targeting miR-150-5p.

show abstract

“…MiR-150 expression is decreased in the serum of PD patients and could be as a candidate diagnostic biomarker for PD. Overexpressing miR-150 repressed lipopolysaccharide (LPS) mediated microglial inflammation [ 15 ]. Cai LJ et al found that up-regulating miR-375 alleviated the damage of dopaminergic neurons, and reduced oxidative stress and inflammation by inhibiting SP1 in 6-hydroxydopamine induced PD animal model [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson's disease model via targeting miR-124-3p mediated FSTL1/NF-κB axis

Cao¹,

Han²,

Jia³

et al. 2021

Aging

View full text Add to dashboard Cite

Background: Studies have revealed that lncRNA HOXA11-AS contributes to regulating inflammation, while the role of HOXA11-AS in Parkinson’s disease (PD) remains unclear. Methods: Both in vivo and in vitro PD models were induced. Gain- or loss-assays of HOXA11-AS and miR-124-3p were conducted. The neurological functions, dopaminergic neurons damage, microglia activation of PD mice were measured. Afterwards, the expressions of inflammatory factors were examined with RT-PCR. Western blot was employed to detect the level of FSTL1, NF-κB and NLRP3 inflammasome. Meanwhile, bioinformatics analysis and dual-luciferase reporter assay were utilized to confirm the targeting relationships among miR-124-3p, HOXA11-AS and FSTL1. Results: HOXA11-AS promoted MPTP-mediated SH-SY5Y neuronal injury and LPS-induced microglia activation, while miR-124-3p had the opposite effects. Additionally, miR-124-3p was the target of HOXA11-AS and FSTL1. HOXA11-AS overexpression enhanced the expression of inflammatory factors and FSTL1, NF-κB and NLRP3 inflammasome, while inhibiting NF-κB weakened HOXA11-AS-mediated neuronal damage and microglia activation. Moreover, HOXA11-AS1 downregulation ameliorated MPTP-induced neurological damages and neuroinflammation in mice. Conclusion: Inhibition of HOXA11-AS protects mice against PD through repressing neuroinflammation and neuronal apoptosis through miR-124-3p-FSTL1-NF-κB axis.

show abstract

MicroRNA‐150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson's disease

Cited by 42 publications

References 38 publications

MicroRNA Candidate Biomarkers for Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder

MicroRNA Candidate Biomarkers for Parkinson’s Disease and Idiopathic REM Sleep Behavior Disorder

LncRNA RMST Regulates Neuronal Apoptosis and Inflammatory Response via Sponging miR-150-5p in Parkinson’s Disease

Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson's disease model via targeting miR-124-3p mediated FSTL1/NF-κB axis

Contact Info

Product

Resources

About